文献速递乳腺癌妇科肿瘤

遗传性乳腺癌卵巢癌中双重杂合变异的谱系与临床影响

Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancer.
PubMed 文献 · Eur J Cancer · 2026-06-11

基于德国全国HBOC登记处的前瞻性数据,对26983例单或多重致病变异携带者进行病例对照研究,发现多重杂合占2.9%(98/3407,13核心基因亚组),400例为双重杂合。BRCA1与其他基因双重杂合者的乳腺癌表型受基因组合影响,且BRCA1/BRCA2双重杂合者疾病严重程度高于单杂合者。

要点

  • HBOC核心基因多重杂合频率高于既往假设,13基因检测亚组中占2.9%。
  • BRCA1/其他基因双重杂合乳腺癌多为三阴性,但BRCA1/CHEK2者HR阳性比例高于BRCA1单杂合。
  • BRCA1/BRCA2双重杂合者疾病严重程度高于匹配的单杂合携带者。

核心结论

  • HBOC核心基因多重杂合比既往认为的更常见,基因-基因组合可重塑肿瘤表型和临床严重程度,而非遵循单基因预期。

研究设计与样本

  • 基于德国全国HBOC登记处的前瞻性数据,开展病例对照研究,匹配女性携带者比较多重与单杂合致病变异携带者的癌症风险和疾病严重程度。
  • 共纳入26983例单或多重HBOC相关致病变异携带者,其中409例有多重杂合,包括400例双重杂合。

主要发现

  • 在检测13个核心基因的亚组中,98/3407(2.9%)个体携带多重HBOC相关致病变异。
  • BRCA1与另一基因双重杂合的女性乳腺癌 predominantly 为三阴性,即使第二个非BRCA1致病变异通常与HR阳性乳腺癌相关。
  • BRCA1/CHEK2双重杂合携带者HR阳性乳腺癌比例高于BRCA1单杂合女性。
  • 女性ATM/CHEK2双重杂合与BRCA1单杂合携带者首次乳腺癌中位年龄相似(41.5 [IQR 14.0] vs. 41.3 [14.1]岁)。
  • 匹配的BRCA1和BRCA2单杂合携带者出现更高疾病严重程度的可能性低于BRCA1/BRCA2双重杂合携带者(BRCA1: OR 0.396 [0.180-0.87];BRCA2: OR 0.224 [0.100-0.50])。

临床怎么用

  • 在广泛多基因检测时代,应将多重致病变异纳入风险评估和咨询,以优化双重杂合个体及家系的个性化监测和降低风险策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: (Likely) pathogenic variants (pVs) in hereditary breast and/or ovarian cancer (HBOC) genes increase cancer risk, but the clinical implications of multiple pVs remain insufficiently understood. METHODS: Using data from the prospective nationwide German Consortium for HBOC registry, we conducted a case-control study of genotype-phenotype associations, matching female carriers to compare cancer risk and disease severity between multiple and single heterozygous (SH) pV carriers. RESULTS: Among 26,983 carriers of single or multiple HBOC-associated pVs, 409 individuals had multiple heterozygosities, including 400 double heterozygous (DH) carriers. In a subcohort tested for 13 core genes, 98/3407 (2.9%) individuals had multiple HBOC-associated pVs. Breast cancers (BCs) in DH women with pVs in BRCA1 and another gene were predominantly triple-negative, even when the second, non-BRCA1 pV was typically associated with hormone receptor (HR)-positive BC. By contrast, BRCA1/CHEK2 DH carriers showed more HR-positive BCs than BRCA1 SH women. The median age at first BC was similar in female ATM/CHEK2 DH carriers and BRCA1 SH carriers (41.5 [IQR 14.0] vs. 41.3 [14.1] years). Matched BRCA1 and BRCA2 SH carriers were less likely to present with higher disease severity than BRCA1/BRCA2 DH carriers (BRCA1: OR 0.396 [0.180-0.87]; BRCA2: OR 0.224 [0.100-0.50]). CONCLUSIONS: Multiple heterozygosity in HBOC core genes is more frequent than previously assumed. Our data indicate that gene-gene constellations can reshape tumour phenotype and clinical severity rather than following single-gene expectations. Integrating multiple pVs into risk assessment and counselling may enhance personalised surveillance and risk-reducing strategies for DH individuals and their families in the era of widespread multigene testing.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Herold N, Engel C, Speiser D, et al. Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancer. Eur J Cancer. 2026. PMID: 42341617. doi:10.1016/j.ejca.2026.116874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。